Advertisement

Control of paroxysmal atrial fibrillation recurrence using combined administration of propafenone and quinidine

      Abstract

      The frequent recurrence of paroxysmal atrial fibrillation (PAF) despite the use of standard antiarrhythmic agents prompted the use of new therapeutic approaches. There are few data on systematic assessment of PAF control with stepwise dose escalation and the use of a drug combination. Low-dose quinidine may promote the efficacy of propafenone by inhibiting its degradation through the cytochrome P450 pathway (CYP2D6). We prescribed propafenone 300 to 450 mg/day to 60 patients with PAF for 8 weeks, and 62% were symptomatically controlled. The 19 refractory patients were randomized in a double-blinded fashion to receive either a higher dose of propafenone (450 to 675 mg/day) or the standard dose of propafenone with low-dose quinidine 150 mg/day, each for an 8-week study period, and subsequently crossed over to the alternative treatment. The resulting serum propafenone concentrations were 259 ± 208 and 336 ± 237 mg/day (p >0.5), respectively. Both treatment arms prolonged the time to the first symptomatic atrial fibrillation (AF) recurrence and the interval between attacks, and AF was controlled in 37% of patients. However, the higher dose of propafenone was associated with gastrointestinal side effects not present with the low-dose quinidine combination. Of the 10 refractory patients, 7 were further controlled with a standard dose of propafenone plus quinidine (600 mg/day). Overall, control of PAF was achieved in 85% of patients at the end of 8 months; adverse effects necessitating withdrawal were observed in 6%, and uncontrolled AF in 5% of patients. There was no difference in the mean AF rate during recurrences in all phases, and ventricular proarrhythmia was not seen. This study documents the role of stepwise antiarrhythmic treatment of PAF. The use of a standard dose of propafenone, followed by low-dose quinidine combination to reduce propafenone degradation, and the combined standard dose of propafenone and quinidine may be used to maximize efficacy and tolerability.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Narayan S.M.
        • Cain M.E.
        • Smith J.M.
        Atrial fibrillation.
        Lancet. 1997; 350: 943-950
        • Coplen S.E.
        • Antman E.M.
        • Berlin J.A.
        • Hewitt P.
        • Chalmers T.C.
        Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.
        Circulation. 1990; 82: 1106-1116
        • Morganroth J.
        • Goin J.E.
        Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias. A meta-analysis.
        Circulation. 1991; 84: 1977-1983
        • Feld G.K.
        Atrial fibrillation. Is there a safe and highly effective pharmacological treatment?.
        Circulation. 1990; 82: 2248-2250
        • Grace A.A.
        • Camm A.J.
        Quinidine.
        N Engl J Med. 1998; 338: 35-45
        • Connolly S.J.
        • Hoffert D.L.
        Usefulness of propafenone for recurrent paroxysmal atrial fibrillation.
        Am J Cardiol. 1989; 63: 817-819
        • Shen E.N.
        • Keung E.
        • Huycke E.
        • Dohrmann M.L.
        • Nguyen N.
        • Morady F.
        • Sung R.J.
        Intravenous propafenone for termination of reentrant supraventricular tachycardia. A placebo-controlled, randomized, double-blind, crossover study.
        Ann Intern Med. 1986; 105: 655-661
        • Antman E.M.
        • Beamer A.D.
        • Cantillon C.
        • McGowan N.
        • Goldman L.
        • Friedman P.L.
        Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter.
        J Am Coll Cardiol. 1988; 12: 1005-1011
        • Capucci A.
        • Boriani G.
        • Rubino I.
        • Della C.S.
        • Sanguinetti M.
        • Magnani B.
        A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm.
        Int J Cardiol. 1994; 43: 305-313
        • Pritchett E.L.
        • McCarthy E.A.
        • Wilkinson W.E.
        Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy.
        Ann Intern Med. 1991; 114: 539-544
        • Hammill S.C.
        • Wood D.L.
        • Gersh B.J.
        • Osborn M.J.
        • Holmes D.R.J.
        Propafenone for paroxysmal atrial fibrillation.
        Am J Cardiol. 1988; 61: 473-474
        • Stroobandt R.
        • Stiels B.
        • Hoebrechts R.
        Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators.
        Am J Cardiol. 1997; 79: 418-423
        • Anderson J.L.
        • Gilbert E.M.
        • Alpert B.L.
        • Henthorn R.W.
        • Waldo A.L.
        • Bhandari A.K.
        • Hawkinson R.W.
        • Pritchett E.L.
        Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group.
        Circulation. 1989; 80: 1557-1570
        • Lau C.P.
        • Leung W.H.
        • Wong C.K.
        A randomized double-blind crossover study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation.
        Am Heart J. 1992; 124: 645-650
        • Middlekauff H.R.
        • Wiener I.
        • Stevenson W.G.
        Low-dose amiodarone for atrial fibrillation.
        Am J Cardiol. 1993; 72: 75F-81F
        • Wilson J.S.
        • Podrid P.J.
        Side effects from amiodarone.
        Am Heart J. 1991; 121: 158-171
        • Fuchs T.
        • Podrid P.J.
        Pharmacologic therapy for reversion of atrial fibrillation and maintenance of sinus rhythm.
        in: Falk R.H. Podrid P.J. Atrial Fibrillation Mechanisms and Management. Raven Press, New York1992: 233-254
        • Chow M.S.
        • Lebsack C.
        • Hilleman D.
        Propafenone.
        Clin Pharmacol. 1988; 7: 869-877
        • Siddoway L.A.
        • Thompson K.A.
        • McAllister C.B.
        • Wang T.
        • Wilkinson G.R.
        • Roden D.M.
        • Woosley R.L.
        Polymorphism of propafenone metabolism and disposition in man.
        Circulation. 1987; 75: 785-791
        • Lou Y.C.
        • Ying L.
        • Bertilsson L.
        • Sjoqvist F.
        Low frequency of slow debrisoquine hydroxylation in a native Chinese population.
        Lancet. 1987; 2: 852-853
        • Klein R.C.
        • Huang S.K.
        • Marcus F.I.
        • Horwitz L.
        • Fenster P.E.
        • Rushforth N.
        • Kirsten E.B.
        Enhanced antiarrhythmic efficacy of propafenone when used in combination with procainamide or quinidine.
        Am Heart J. 1987; 114: 551-558
        • Kim S.G.
        • Seiden S.W.
        • Matos J.A.
        • Waspe L.E.
        • Fisher J.D.
        Combination of procainamide and quinidine for better tolerance and additive effects for ventricular arrhythmias.
        Am J Cardiol. 1985; 56: 84-88
        • Greenspan A.M.
        • Spielman S.R.
        • Webb C.R.
        • Sokoloff N.M.
        • Rae A.P.
        • Horowitz L.N.
        Efficacy of combination therapy with mexiletine and a type IA agent for inducible ventricular tachyarrhythmias secondary to coronary artery disease.
        Am J Cardiol. 1985; 56: 277-284
        • Antman E.M.
        • Beamer A.D.
        • Cantillon C.
        • McGowan N.
        • Friedman P.L.
        Therapy of refractory symptomatic atrial fibrillation and atrial flutter.
        J Am Coll Cardiol. 1990; 15: 698-707
        • Crijns H.J.
        • Van Gelder I.C.
        • Van Gilst W.H.
        • Hillege H.
        • Grosselink A.M.
        • Lie K.I.
        Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter.
        Am J Cardiol. 1991; 68: 335-341